By treating AdCC cell line with BIRC5 siRNA or YM155, a novel imidazolium-based compound[45], we observed a reduced cell proliferation, increase of apoptosis as well as autophagic cell death[30], which further demonstrates the tumor-promoting role of survivin in AdCC. Here, BIRC5 is linked to adrenocortical carcinoma, hereditary.